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Abstract
Background: While often life-saving, treatment for head and neck cancer (HNC) can be debilitating resulting in
unplanned hospitalization. Hospitalizations in cancer patients may disrupt treatment and result in poor outcomes.
Pre-treatment muscle quality and quantity ascertained through diagnostic imaging may help identify patients at high
risk of poor outcomes early. The primary objective of this study was to determine if pre-treatment musculature was
associated with all-cause mortality.
Methods: Patient demographic and clinical characteristics were abstracted from the cancer center electronic data‑
base (n = 403). Musculature was ascertained from pre-treatment CT scans. Propensity score matching was utilized to
adjust for confounding bias when comparing patients with and without myosteatosis and with and without low mus‑
cle mass (LMM). Overall survival (OS) was evaluated using the Kaplan–Meier method and Cox multivariable analysis.
Results: A majority of patients were male (81.6%), white (89.6%), with stage IV (41.2%) oropharyngeal cancer (51.1%)
treated with definitive radiation and chemotherapy (93.3%). Patients with myosteatosis and those with LMM were
more likely to die compared to those with normal musculature (5-yr OS HR 1.55; 95% CI 1.03–2.34; HR 1.58; 95% CI
1.04–2.38).
Conclusions: Musculature at the time of diagnosis was associated with overall mortality. Diagnostic imaging could
be utilized to aid in assessing candidates for interventions targeted at maintaining and increasing muscle reserves.
Keywords: Head and neck cancer, Muscle density, Body composition, Mortality, Radiotherapy, CCRT
Introduction
The treatments and side effects for head and neck cancer (HNC) can be dramatic in patients undergoing concomitant chemoradiation therapy (CCRT). CCRT in
those with advanced HNC can produce grade 3 or worse
toxicities including: hematological toxicities (decreases
in bone marrow and blood cell counts that can lead to
anemia, bleeding or infection), gastrointestinal reactions
(nausea and vomiting), dermatitis, and mucositis; the
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adverse effects of treatment can be so severe as to require
unplanned hospitalizations and can lead to treatment
delay or interruption [1]. A treatment delay or interruption may in turn lead to an avoidable death.
A routine part of both diagnosis and treatment for
HNC patients receiving definitive radiation therapy (RT)
for HNC is computed tomography (CT) imaging which
captures measures of body composition including muscle mass and muscle density. Skeletal muscle density
(SMD), as measured through CT, refers to the radiodensity of the muscle fibers as found in muscle tissue; muscle
density is inversely proportional to the amount of fatty
infiltration into the muscle tissue, or myosteatosis sometimes referred to as muscle quality. Muscle mass can be
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compared between patients after CT measurement by
calculating the skeletal muscle index (SMI). Since CT is
routinely performed on HNC patients receiving definitive
RT, SMD and SMI could be ascertained more regularly
without causing additional patient burden. By ascertaining SMD and SMI, it may be possible to identify patients
at risk for complications and poor outcomes during and
after cancer treatment. Cancer patients facing unplanned
hospitalization during cancer care are at increased risk
of moderate to severe fatigue, depression, and post-traumatic stress disorder and may have to delay or stop their
cancer treatment [2].
The aim of the current study was to evaluate the relationship between pre-treatment musculature and allcause mortality in HNC patients. We hypothesized
that those with poor musculature would have higher
risk of dying from all causes than those with normal
musculature.

Methods
Study design and population

We conducted a retrospective cohort study including
survival analysis on a sample of squamous cell HNC
patients treated with definitive radiation therapy over
18 years of age at Roswell Park Comprehensive Cancer Center (RPCCC), a facility in Western New York
between 2008 and 2017. Those without readable wholebody -CT scans of the third lumbar (L3) vertebral body
were excluded. Those persons where contrast dye was
utilized were also excluded as contrast dye has been
shown to alter the reported density of muscle tissue [3].
Survival was ascertained through clinical follow‐up, electronic medical record search, and follow‐up phone calls
to patients and family members. The Institutional Review
Board at RPCCC approved the study.
Marker measurement

Imaging software (SliceOmatic Software by TomoVision, version 5.0) was used to quantify the cross-sectional
area of muscle (a measure of skeletal muscle mass) and
adipose tissue (in centimeters squared) at L3. The imaging software allows for measurement of skeletal muscle,
visceral adipose tissue, subcutaneous adipose tissue, and
intermuscular adipose tissue through the use of tissuespecific Hounsfield Units (HU) ranges [4]. The L3 level
is used when estimating body composition as the estimates of skeletal muscle mass were previously and extensively validated based on measurements taken from the
slice at this level of the body [5]. Other validation studies
have shown that estimates of other whole body volumes
from the L3 level are valid including fat estimates [6]. A
measure of skeletal muscle mass, skeletal muscle index
(SMI) was created by adjusting muscle mass for patient
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height (calculated by dividing the muscle area at L3 by
patient height in meters squared). This adjustment is
completed to enable comparisons between subjects and
to determine low muscle mass (LMM). Skeletal muscle
radiodensity (SMD), as measured by the mean radiation
attenuation in HU, was used as the measure of muscle
density.
SliceOmatic was also used to quantify adipose tissue in centimeters squared at the L3 level using the
same method as described above [4]. Total adipose tissue (TAT) area at L3 in cm2 was constructed through
addition of visceral adipose tissue (VAT), subcutaneous
adipose tissue (SAT) and intermuscular adipose tissue
(IMAT) and each was reported.
Covariates and confounders

Age was expressed in years and parameterized as a continuous variable. Sex was parameterized as a dichotomous variable. Primary tumor site was recorded and
reported as oropharynx, laryngeal, and other. Smoking status was categorized as current (an active daily
smoker), former (an individual who has quit smoking at
some point in the past and is now smoke-free), or never
smoker (an individual who has never smoked). HPV was
categorized as positive, negative, or inapplicable. Number of comorbidities was captured and parameterized
as continuous. Staging of the tumor was categorized
according to AJCC staging. Treatment was reported as
follows: radiation therapy alone or radiation therapy
plus chemotherapy. Median age of 61 years was utilized during analysis. Muscle density was dichotomized
as myosteatosis and normal according to BMI appropriate cut-offs for head and neck cancer as previously
described excluding the requirement for ≥ 8% weight
loss as this is not a consistent criterion [7, 8]. Myosteatosis based on low muscle radiodensity has been used
extensively in the literature. Myosteatosis was defined
as < 41 Hounsfield units (HU) for those with a BMI in
the healthy or underweight range (≤ 24.9) and < 33 HU
for those with a BMI in the overweight or obese range
(≥ 25.0) [7, 9]. Low muscle mass (LMM) was defined
as SMI < 41 cm2/m2 in females and SMI < 43 cm2/m2 in
males if of a normal BMI (BMI < 25 kg/m2) and LMM
was SMI < 53 cm2/m2 if BMI ≥ 25 kg/m2 as done in
prior studies [7, 9]. Unplanned hospitalization within
3 months after completing RT was dichotomous (yes vs
no). Overall survival (OS) was defined as time interval
from diagnosis to last follow up or death by any cause.
Statistical analysis

To compare categorical and continuous variables in
patients with and without unplanned hospitalizations,

Shaver et al. BMC Cancer

(2022) 22:688

Fisher’s exact tests and student’s t-tests were performed,
as appropriate.
Cox multivariable regression analysis was performed to
evaluate variables associated with OS, after adjusting for
age, gender, race, tumor stage, tumor site, treatment type,
human papilloma virus (HPV) status, comorbidity, alcohol intake, and smoking status. Kaplan–Meier and logrank tests were also performed to analyze OS. Propensity
score matching in patients for myosteatosis and LMM
was performed to control for confounding bias. Matching
characteristics included clinically relevant variables used
for Cox multivariable regression analysis. Matching was
based on nearest neighbor method in a 1:1 ratio with no
replacement and a caliper distance of 0.2 of the standard
deviation of the logit of the propensity score [10, 11].
All p values were two-sided and variables with p ≤ 0.05 were
considered significant. Statistical analyses were performed
using SAS (SAS Institute, Cary, NC) and R (R Project for
Statistical Computing, version 4.0.2).

Results
Population characteristics at baseline

Data from 403 patients were analyzed for this study
(flowchart of included subjects Supplemental Figure 1). Baseline demographics and physical characteristics of patients prior to matching were recorded
(Table 1). Median follow up was 64.5 months (interquartile range 40.3–87.1). The average age of patients was
60.9 ± 10.3 years and the majority were white (89.6%)
and male (81.6%). The average number of comorbidities was nearly 2 (2.2 ± 1.8). Most patients were former
smokers (50.1%), current alcohol drinkers (56.6%) and
overweight (mean BMI 27.8 ± 5.8).
A majority of patients had oropharyngeal cancer (51.1%
overall) followed by laryngeal cancer (24.8%) and only
just over one-third had HPV-associated tumors (40.7%).
The distribution of stage from I-IV was as follows: 0.3%
at stage 0, 4.2% at stage I, 29.5% at stage II, 24.8% at stage
III, and 41.2% at stage IV. A vast majority of patients were
treated with both definitive radiation and chemotherapy
(93.3%), while the remainder of patients were treated
with radiation alone (6.7%).
The average skeletal muscle density (SMD) among
those with myosteatosis was 30.5 ± 5.8 HU and the
average skeletal muscle index was 44.3 ± 8.4 cm2/m2;
whereas among normal musculature these compositional
measures were 43.4 ± 5.3 HU and 58.3 ± 10.1 cm2/m2,
respectively. Total adipose tissue was different between
the two groups (p < 0.0001) with the largest difference
occurring in visceral adipose tissue (VAT). Within the
baseline cohort, 135 patients (33.5%) had low muscle
mass (LMM). Of those with LMM, 85 had co-occurring
myosteatosis. There were 95 unplanned hospitalizations
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during the study period accounting for an incidence proportion of 23.6%.
Mortality

During the study period, 180 persons died producing a
mortality rate of 44.7%. Prior to matching, our Cox multivariable analysis showed both LMM (HR 1.25, 95% CI
0.89–1.75, p = 0.19) and myosteatosis (HR 1.14, 95% CI
0.81–1.60, p = 0.46) were not associated with OS.
After matching, all variables were well balanced
(Table 2). A total of 98 and 102 matched pairs were identified for those with versus without myosteatosis and low
versus normal muscle mass, respectively. Patients with
myosteatosis were associated with worse OS (5-year OS
55.8% vs 63.4%; HR 1.55, 95% CI 1.03–2.34, p = 0.037;
Fig. 1). Patients with LMM were associated with worse
OS (5-year OS 52.9% vs 67.3%; HR 1.58, 95% CI 1.04–
2.38, p = 0.032; Fig. 2).

Discussion
The results of the study indicated that baseline musculature (both myosteatosis and low muscle mass) was
predictive of all-cause mortality in this cohort of HNC
patients. Low muscle mass has been tied to chemotoxicity through a number of mechanisms. Chemotherapy and
radiation can cause muscle wasting via inflammation and
activation of the NF-κB pathway [12, 13]. Those patients
with less dense muscle or, less muscle mass at the beginning of therapy may be less likely to tolerate full therapy
and therefore more likely to succumb to their cancer [14].
The study population was in accord with HNC populations typical of the United States: the study population
was predominately male, non-Hispanic white, with an
oropharyngeal primary tumor site [15]. Our measure of
SMD was slightly higher than a prior study of myosteatosis and sarcopenia in HNC patients (38.6 vs 30.5 HU
at baseline) [7]. Our measure of SMD was in accord with
other studies of different cancer patients prior to treatment [16, 17]. A systematic review found a wide range
of prevalence in sarcopenic and low muscle mass definitions. Pre-treatment prevalence ranged from 6.6–70%
in HNC patients [18]. The review found that low muscle
mass was associated with decreased overall survival but
that more studies were needed to verify the findings.
A recent prospective cohort study by Thureau et al.
examined the relationship between pre-treatment sarcopenia (determined solely through CT evaluation at the
L3 level) and both treatment-related toxicities and overall survival [19]. The current study was in accord with
the prospective cohort study’s findings. The Thureau
et al. study found that although sarcopenia did not have
an association with treatment related toxicity there was a
significant association with overall survival HR 1.9 (95%
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Fig. 1 Overall Survival Myosteatosis compared to No Myosteatosis

CI 1.1, 3.25) which is in line with the findings of the current study.
A similarly sizedstudy (matched sample n = 100 vs
n = 99) by Findlay et al. indicated that treatment completion was similar for those HNC patients with and without pre-treatment myosteatosis while including a much
higher percentage of stage IV cancers (62%) [7]. The same
study found not significant association between pretreatment myosteatosis and unplanned hospitalization
(OR 3.45; 95% CI 0.93, 12.64; p = 0.063). The Findlay et al.
study performed a survival analysis and also found similar
associations to the current study between overall survival,
baseline LMM (HR 3.87; 95% CI 1.22, 12.24; p = 0.02) and
myosteatosis (HR 8.86; 95% CI 1.12, 69.88; p = 0.038).
A retrospective cohort study was conducted at the
University Medical Center Utrecht on locally advanced
HNC patients treated with chemoradiation. The study
was conducted in a similar timeframe to this study from
2012 to 2018. Chargi et al. also found that low skeletal
muscle mass at diagnosis was prognostic for overall survival (HR 2.1; 95% CI 1.1–4.1; p = 0.03).
Muscle density and myosteatosis are still relatively new
areas of exploration in HNC and so comparable studies
are limited. A study by Murnane et al. examined the rate

of overall survival and complications following radical
surgery in oesophageal and gastric cancer patients. Those
with myosteatosis compared to normal musculature had
a reduced 5 year overall (54.1 vs. 83%, p = 0.004) and disease-free (55.2 vs. 87.2%, p = 0.007) survival.
A study by Charette et al. performed a post-hoc analysis of two clinical trials on colorectal cancer patients [20].
The post-hoc analysis indicated that myosteatosis was
indicative of poor survival which is similar to the findings of this study. Charette et al. also found that the factor
with the most negative impact on survival was visceral
adipose tissue and those are the persons in the current
study who were hospitalized at a higher percent.
A recent study by Schaffler-Schaden et al. failed to
find a significant association between visceral adiposity, BMI, myosteatosis, and complications following surgery with curative intent in colorectal cancer patients
[21]. The Schaffler-Schaden et al. study indicated that in
the non-obese population the only statistically significant predictor was lean muscle mass. It is possible that
the effect of myosteatosis is different in the non-obese
population.
The study had a number of strengths. The study
was a cohort design allowing for the exposure to be
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Table 1 Patient characteristics overall and according to muscle density
Characteristic

All n = 403

Myosteatosis n = 150 (37.2)

Normal Musculature n = 253 (62.8)

p

Age (years)

60.9 (10.3)

65.2 (10.9)

58.4 (9.0)

< 0.0001

Male

329 (81.6)

97 (64.7)

232 (91.7)

Female

74 (18.4)

53 (35.3)

21 (8.3)

White

361 (89.6)

130 (86.7)

231 (91.3)
22 (8.7)

Sex

< 0.0001

Race

0.14

BIPOC

42 (10.4)

20 (13.3)

BMI (kg/m2)

27.8 (5.8)

25.3 (6.1)

29.3 (5.1)

< 0.0001

SMI (cm2/m2)

53.1 (11.7)

44.3 (8.4)

58.3 (10.1)

< 0.0001

VAT (cm2)

163.3 (96.3)

129.6 (88.1)

183.3 (95.5)

< 0.0001

SAT (cm2)

181.4 (94.7)

165.7 (102.9)

190.7 (88.5)

0.01

IMAT (cm2)

13.0 (8.1)

16.4 (9.3)

11.0 (6.5)

< 0.0001

TAT (cm2)

357.7 (164.5)

311.8 (168.0)

385.0 (156.4)

< 0.0001

SMD (HU)

38.6 (8.3)

30.5 (5.8)

43.4 (5.3)

< 0.0001

135 (33.5)

85 (56.7)

50 (19.8)

Low Muscle Mass
Yes

< 0.0001

No

268 (66.5)

65 (43.3)

203 (80.2)

Comorbidities

2.2 (1.8)

2.3 (1.8)

2.1 (1.9)

206 (51.1)

61 (40.7)

145 (57.3)

Tumor site
Oropharynx

0.001

Larynx

100 (24.8)

51 (34.0)

49 (19.4)

Other

32 (7.9

38 (25.3)

59 (23.3)

137 (34.0)

39 (26.0)

98 (38.7)

AJCC stage
0-II

0.005

III

100 (24.8)

40 (26.7)

60 (23.7)

IV

166 (41.2)_

71 (47.3)

95 (37.6)

164 (40.7)

40 (26.7)

124 (49.0)

HPV
Positive

< 0.0001

Negative

96 (23.8)

48 (32.0)

48 (19.0)

Inapplicable

143 (35.5)

62 (41.3)

81 (32.0)

RT only

27 (6.7)

18 (12.0)

9 (3.6)

RT + Chemotherapy

376 (93.3)

132 (88.0)

244 (96.4)

Current

110 (27.3)

50 (33.3)

60 (23.7)

Treatment

0.001

Smoking status

0.02

Former

202 (50.1)

76 (50.7)

126 (49.8)

Never

91 (22.6)

24 (16.0)

67 (26.5)

228 (56.6)

81 (54.0)

147 (58.1)

Alcohol consumption
Current

0.33

0.41

Former

88 (21.8)

37 (24.7)

51 (20.2)

Never

69 (17.1)

23 (15.3)

46 (18.2)

Unknown

18 (4.5)

9 (6.0)

9 (3.6)

None

308 (76.4)

121 (80.7)

187 (73.9)

One

95 (23.6)

29 (19.3)

66 (26.1)

Unplanned hospitalizations

0.12

Abbreviations: AJCC American Joint Committee on Cancer, AMS Altered mental status, BMI Body mass index, HNC Head and neck cancer, HU Hounsfield Units, HPV
Human papilloma virus, IMAT Intermuscular adipose tissue, kg kilograms, SAT Subcutaneous adipose tissue, SMD Skeletal muscle density, SMI Skeletal muscle index,
TATTotal adipose tissue, VAT Visceral adipose tissue
Data are presented as frequency (percent), mean (SD), or median (IQR)

ascertained prior to the outcome. Only patients with
imaging of L3 were included which allowed for consistency in the measurement of body composition

parameters and served to decrease measurement bias.
Patient scans were only be used if they were full-body
CT scans thus improving rigor and reproducibility.
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Table 2 Characteristics of matched pairs
Myosteatosis n = 98

No Myosteatosis n = 98

N

%

N

%

< 61

62

63.3

64

65.3

>  = 61

36

36.7

34

34.7

Age

p

LMM n = 102

Normal MM n = 102

N

%

N

%

68

66.7

69

67.6

34

33.3

33

32.4

18

17.6

16

15.7

84

82.4

86

84.3

94

92.2

92

90.2

8

7.8

10

9.8

0.88

Sex

1

0.60

Female

22

22.4

18

18.4

Male

76

77.6

80

81.6

Race

0.85

0.65

White

86

87.8

89

90.8

BIPOC

12

12.2

9

9.2

Comorbidities

0.81

0.96

0.86

None

16

16.3

18

18.4

17

16.7

19

18.6

1

25

25.5

27

27.6

25

24.5

27

26.5

2

16

16.3

14

14.3

14

13.7

16

15.7

3+

41

41.8

39

39.8

46

45.1

40

39.2

Oropharynx

44

44.9

46

46.9

48

47.1

53

52.0

Larynx

31

31.6

33

33.7

32

31.4

26

25.5

Other

23

23.5

19

19.4

22

21.6

23

22.5

Tumor site

0.79

AJCC stage

0.66

0.34

0.98

0-II

28

28.6

32

32.7

30

29.4

32

31.4

III

19

19.4

25

25.5

24

23.5

24

23.5

IV

51

52.0

41

41.8

48

47.1

46

45.1

HPV

0.81

0.68

Positive

21

21.4

23

23.5

22

21.6

26

25.5

Negative

29

29.6

32

32.7

35

34.3

37

36.3

N/A

48

49.0

43

43.9

45

44.1

39

38.2

6

5.9

6

5.9

96

94.1

96

94.1

Treatment

1

RT only

7

7.1

8

8.2

Chemoradiation

91

92.9

90

91.8

Smoking

1

0.98

0.80

Current

20

20.4

20

20.4

22

21.6

26

25.5

Former

45

45.9

47

48.0

50

49.0

48

47.1

Never

33

33.7

31

31.6

30

29.4

28

27.5

Alcohol

0.92

0.75

Current

18

18.4

18

18.4

19

18.6

16

15.7

Former

20

20.4

21

21.4

20

19.6

26

25.5

Never

56

57.1

57

58.2

60

58.8

58

56.9

N/A

4

4.1

2

2.0

3

2.9

2

2.0

0

0.0

102

100.0

102

100.0

0

0.0

Muscle mass

1

Normal

49

50.0

48

49.0

Low

49

50.0

50

51.0

Myosteatosis

p

NA

NA

1

No

0

0.0

98

100.0

53

52.0

53

52.0

Yes

98

100.0

0

0.0

49

48.0

49

48.0

Abbreviations: AJCC American Joint Committee on Cancer, BIPOC Black Indigenous People of Color, LMM Low muscle mass, MM Muscle mass, RT Radiation therapy
Data are presented as frequency (percent), mean (SD)
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Fig. 2 Overall Survival Low Muscle Mass compared to Normal Muscle Mass

All patients were managed by one radiation oncologist
which allowed for consistency in care decisions.
The study also had some limitations. The study contains patients with multiple cancer sites, however an
attempt was made to control for this by including it in
the final model. The study is also a single-center study
and so its findings may not be broadly applicable.
The pre-treatment prevalence of myosteatosis and
low muscle mass was 37.2 and 33.5%, respectively. Both
myosteatosis and low muscle mass were significantly associated with mortality. The question of musculature and
treatment effects requires more study so as to determine
an appropriate and feasible response. Diagnostic and planning imaging could potentially be utilized to give early and
specific body composition and malnutrition information
to the healthcare team in an effort to improve outcomes.
Abbreviations
AJCC: American Joint Committee on Cancer; BMI: Body mass index; CCRT:
Concomitant chemoradiation therapy; CT: Computed tomography; HNC: Head
and neck cancer; HU: Hounsfield Units; HPV: Human papilloma virus; IMAT:
Intermuscular adipose tissue; Kg: Kilograms; LMM: Low Muscle Mass; MM: Mus‑
cle Mass; OR: Odds ratios; RPCCC: Roswell Park Comprehensive Cancer Center;
SAT: Subcutaneous adipose tissue; SMD: Skeletal muscle density; SMI: Skeletal
muscle index; TAT: Total adipose tissue; VAT: Visceral adipose tissue.
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